Woodline Partners LP Liquidia Corp Transaction History

Woodline Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$6.63 - $9.9 $258,570 - $386,100	-39,000 Reduced 12.78%	266,273 $2.09 Million
Q1 2023 May 15, 2023	BUY	$5.72 - $7.91 $1.11 Million - $1.53 Million	193,458 Added 173.02%	305,273 $2.11 Million
Q4 2022 Feb 14, 2023	SELL	$4.68 - $6.54 $2.34 Million - $3.27 Million	-500,243 Reduced 81.73%	111,815 $712,000
Q3 2022 Nov 14, 2022	BUY	$3.73 - $8.39 $2.28 Million - $5.14 Million	612,058 New	612,058 $3.33 Million

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.